Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Patients' Access to Treatments Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
H.R. 1600 (Patient Access to Treaments Act); oral parity; exclusivity incentives for dormant therapies; proposed changes to FDA-authorized risk evaluation and mitigation strategies
patent issues in China; patent issues in Canada; issues related to the Patent Trial and Appeal Board; implementation of patent linkage mechanisms; H.R.9 (Innovation Act); S. 632 (STRONG Patents Act)
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
CELGENE CORPORATION via CELGENE CORPORATION
2015 · first_quarter · Q1
patent issues in China; patent issues in Canada; issues related to the Patent Trial and Appeal Board; implementation of patent linkage mechanisms; H.R.9 (Innovation Act); S. 632 (STRONG Patents Act)
H.R. 1600 (Patient Access to Treaments Act); oral parity; exclusivity incentives for dormant therapies; proposed changes to FDA-authorized risk evaluation and mitigation strategies
Source: Senate LDA
patent issues in China; patent issues in Canada; issues related to the Patent Trial and Appeal Board; implementation of patent linkage mechanisms; H.R.9 (Innovation Act); S. 632 (STRONG Patents Act)
Cancer Drug Coverage Parity Act of 2013
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
REMS proposals, including Stivers-Welch (H.R. 5657); MODDERN Cures Act (H.R. 3116); oral parity (H.R. 1801); specialty tier/cost sharing (H.R. 460); proposed orphan drug policies; other issues related to dormant therapies, including proposed legislation to expand incentives
Cancer Drug Coverage Parity Act of 2013
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
-oral oncology parity (H.R. 1801) -340(b) organization and ongoing implementation -Medicare Parts B&D -implementation of Affordable Care Act-speciality tiers related to pharmaceuticals -H.R. 3091 (MODDERN Cures Act)
Cancer Drug Coverage Parity Act of 2013
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
issues surrounding oral parity and specialty tiers (H.R. 460 and H.R. 1801); issues surrounding potential new incentives for research into unmet medical needs (H.R. 3116)
-oral oncology parity (H.R. 1801) -340(b) organization and ongoing implementation -Medicare Parts B&D -implementation of Affordable Care Act-speciality tiers related to pharmaceuticals -H.R. 3091 (MODDERN Cures Act)
issues surrounding oral parity and specialty tiers (H.R. 460 and H.R. 1801); issues surrounding potential new incentives for research into unmet medical needs (H.R. 3116)
REMS proposals, including Stivers-Welch (H.R. 5657); MODDERN Cures Act (H.R. 3116); oral parity (H.R. 1801); specialty tier/cost sharing (H.R. 460); proposed orphan drug policies; other issues related to dormant therapies, including proposed legislation to expand incentives
-H.R. 3673
Patients' Access to Treatments Act of 2013
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
REMS proposals, including Stivers-Welch (H.R. 5657); MODDERN Cures Act (H.R. 3116); oral parity (H.R. 1801); specialty tier/cost sharing (H.R. 460); proposed orphan drug policies; other issues related to dormant therapies, including proposed legislation to expand incentives
Patients' Access to Treatments Act of 2013
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
issues surrounding oral parity and specialty tiers (H.R. 460 and H.R. 1801); issues surrounding potential new incentives for research into unmet medical needs (H.R. 3116)
Fair Access for Safe and Timely Generics Act of 2014
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
REMS proposals, including Stivers-Welch (H.R. 5657); MODDERN Cures Act (H.R. 3116); oral parity (H.R. 1801); specialty tier/cost sharing (H.R. 460); proposed orphan drug policies; other issues related to dormant therapies, including proposed legislation to expand incentives
Fair Access for Safe and Timely Generics Act of 2014
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
coding related to wound care products; proposed changes to REMS (H.R. 5657)
Patent Transparency and Improvements Act of 2013
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
-U.S. policy with respect to China, Canada, and other countries -Trans-Atlantic Trade and Investment Partnership -Trans-Pacific Partnership -Trade Promotion Authority-patent reform (H.R. 3309 and S. 1720)
H.R. 3091,"MODDERN Cures Act of 2013", all provisions.
-H.R.3091,"MODDERN Cures Act of 2013" (all provisions) -Implementation of Affordable Care Act
negotiations surrounding TPP (Trans-Pacific Partnership) and TTIP (Trans-Atlantic Trade and Investment Partnership); potential grant of Trade Promotion Authority
general issues related to patient access
Filing targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
CELGENE CORPORATION via CELGENE CORPORATION
2014 · fourth_quarter · Q4
Turkey: exchange rate issues; negotiations surrounding TPP (Trans-Pacific Partnership) and TTIP (Trans-Atlantic Trade and Investment Partnership); potential grant of Trade Promotion Authority
issues surrounding oral parity and specialty tiers (H.R. 460 and H.R. 1801); issues surrounding potential new incentives for research into unmet medical needs (H.R. 3116)
coding related to wound care products; proposed changes to REMS (H.R. 5657)
patent issues in China; patent issues in Canada; issues related to the Patent Trial and Appeal Board; implementation of patent linkage mechanisms; IP-related issues in Turkey
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
CELGENE CORPORATION via CELGENE CORPORATION
2014 · third_quarter · Q3
patent issues in China; patent issues in Canada; issues related to the Patent Trial and Appeal Board (United States Patent & Trademark Office); proposed rules related to patent term adjustment (United States Patent & Trademark Office); implementation of patent linkage mechanisms (Republic of Korea)
REMS proposals, including Stivers-Welch (H.R. 5657); MODDERN Cures Act (H.R. 3116); oral parity (H.R. 1801); specialty tier/cost sharing (H.R. 460); proposed orphan drug policies; other issues related to dormant therapies, including proposed legislation to expand incentives
Turkey: exchange rate issues; negotiation of IP-related and other provisions of the Trans-Pacific Partnership; negotiation of IP-related and other provisions of the Transatlantic Trade & Investment Partnership
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
CELGENE CORPORATION via CELGENE CORPORATION
2014 · second_quarter · Q2
implementation of the Affordable Care Act; specialty tier legislation; cost sharing with respect to pharmaceuticals; oral oncology parity
CMS policies related to biomaterials
issues related to patent reform; USPTO practices and procedure; 21st Century Cures Initiative; orphan drug policies
issues relating to the Trans-Pacific Partnership and the Transatlantic Trade & Investment Partnership
implementation of Affordable Care Act
issues related to various patent reform bills; implementation by USPTO of provisions of AIA; implementation of USPTO of various court rulings; treatment of intellectual property by the People's Republic of China; treatment of intellectual property by Canada; intellectual property provisions of the Trans-Pacific Partnership; intellectual property provisions of the Transatlantic Trade & Investment Partnership
implementation of the Affordable Care Act
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)
CELGENE CORPORATION via CELGENE CORPORATION
2014 · first_quarter · Q1
-U.S. policy with respect to China, Canada, and other countries -Trans-Atlantic Trade and Investment Partnership -Trans-Pacific Partnership -Trade Promotion Authority-patent reform (H.R. 3309 and S. 1720)
-H.R. 3673
-oral oncology parity (H.R. 1801) -340(b) organization and ongoing implementation -Medicare Parts B&D -implementation of Affordable Care Act-speciality tiers related to pharmaceuticals -H.R. 3091 (MODDERN Cures Act)
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
CELGENE CORPORATION via CELGENE CORPORATION
2013 · fourth_quarter · Q4
-U.S. policy with respect to China. -U.S. policy with respect to Canada. -U.S. Trans-Atlantic Trade and Investment Partnership. -U.S. Trans-Pacific Partnership.-H.R. 3309, "Innovation Act", issues relating to patent reform. -Trade Promotion Authority.
H.R. 3091,"MODDERN Cures Act of 2013", all provisions.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)
CELGENE CORPORATION via CELGENE CORPORATION
2013 · third_quarter · Q3
-U.S. policy with respect to China -U.S. policy with respect to Canada -U.S. Trans-Atlantic Trade and Investment Partnership -U.S. Trans-Pacific Partnership
-H.R.3091,"MODDERN Cures Act of 2013" (all provisions) -Implementation of Affordable Care Act
-Sequestration of FDA fees
-Taxation of biopharmaceutical companies
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), U.S. Trade Representative (USTR)